CSF3 and neoplasm: Although G-CSF alone showed only a trend toward decreased tumor growth, it accentuated the anti-tumor response of A-1331852, with 25% tumors (6 out of 24) that regressed after 3 weeks, compared to only 1 out of 26 tumors in the single A-1331852 treatment group (Fig. 5C).